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Stress on tiny cell component has dire consequences
Various life sustaining metabolic processes
of animals and humans are powered by energy
converted from food and oxygen by mitochondria. A complex cycle converts glucose and
oxygen into the
energy required
by cells. Mitochondria, tiny
organelles in
cells, have their
own DNA, most
of which is
inherited from
the mother.
Mutations in
mitochondrial
DNA are either
Mitochondria
passed from
mother to child or they may also occur somatically during the early life of the animals.
Within the organelle there are many copies of
the DNA so a mutation may remain dormant
because there are many mitochondria within a
cell. However, over time mutated DNA gets
enriched due to various biochemical factors.
Mutations in mitochondrial DNA also occur
due to external influences like chemicals,
drugs, radiation, and the like, and they become
cumulative as the animal or human ages.
When mutations interfere with the proper
function of the mitochondria disease results.
Dr. Narayan Avadhani, Harriet Ellison
Woodward Professor of Biochemistry at the
School, studies mitochondria. Currently he
and his group are examining the effects of
stress, caused by interruption of the function
of the organelle. It has been known for a number of years that mitochondrial DNA is the
direct and preferential target of attack by varied carcinogens, which cause mutations to the
DNA. The mutations accumulate and eventually interfere with the oxygen utilization and
energy production. Recent work in Dr. Avadhani’s laboratory also showed that mitochondrial DNA or membrane damage also triggers
a stress response cascade through the altered
cellular Ca2+ (calcium ions) pool that causes a
major change in the expression of nuclear
genes and cell morphology.
While investigating mitochondria-to-nucleus stress signaling, the group found that some
of the genes implicated in tumor progression
are activated and overexpressed in otherwise
non-malignant cells when mitochondria are
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stressed. The chemistry within the organelle and
hence in the whole cell is changed as a result of
mitochondrial stress signaling. A change in
mitochondrial membrane property and reduced
energy production in some
cells of a tumor
mass leads to
increased intracellular calcium.
This in turn
leads to the activation of genes
that make cells
more invasive or
metastatic. Such
cells show
increased resistance to apoptosis (cell death) and keep prolifer-

ating. The study shows the existence of a new
pathway for cancer progression, which is activated as part of the mitochondrial genetic and
metabolic stress signaling. The researchers
found that reversal of the mitochondrial stress
in these tumor cells also partly reversed the
mitochondrial stress-induced phenotypic
changes and invasive behavior.
“The stress signaling may therefore be a
critical factor in the ability of some cells within
a tumor mass to acquire invasive phenotypes
and undergo morphological changes leading to
tumor progression and metastasis,” explains
Dr. Avhadhani. “In summary, mitochondrial
dysfunction and the resulting alterations in
nuclear gene expression through mitochondria-to-nucleus stress signaling might be an
important factor in cancer progression and
tumor cell metastasis.”

NIH/Merck Summer student research program
Veterinarians play an important role in all
aspects of biomedical research, in industry,
government agencies and academia. To
encourage students to consider research as a
career, the School, in 1990, initiated a summer
student research program with a grant from
the Merck Foundation, supplemented by
School funds. That year, six students participated in the program. Now the program
receives support from NIH and Merck and the
number of students who received grants in the
summer of 2002 grew to 17.
Students receive a stipend and gain research
experience in all phases of biomedical research.
They work in the laboratories of clinical and
basic researchers at the School as well as at
other locations within the University.
The program enables students to perform
research full time during June, July and August
and participate in weekly seminars as well as a
national meeting in August. Students make
short oral presentation to peers and write a
paper at the end of the summer that is submitted to the School’s Phi Zeta Day.
The program, under the direction of Dr.
Michael Atchison, professor of biochemistry
and director of the V.M.D./Ph.D. program, in
2002 generated such diverse research projects
as those studying detailed molecular-biological
mechanisms of growth control, to studies on
the dynamics of West Nile Virus infection in

the United States. The caliber of the research
performed was outstanding and the application pool continues to grow each year. Since
inception of the program, over 20 research
papers and 11 meeting abstracts have been
published. Considering the short training period, this is an excellent level of productivity.
Since the inception of the program, 156
awards have been funded for 136 students
(some students participate more than once).
Many of the students pursue research careers
after graduation. The current positions of 47
recent graduates (1998-2001) show that 32%
are pursuing post-graduate education (postdoc, graduate program, residency, internship),
57% are in clinical practice, 2% other and the
pursuits of 9% are unknown. Looking further
back to students at least five years out of the
program (1990-1997), current positions are
distributed as follows: 12% academic faculty,
14% post graduate education (postdoc, graduate program, residency, internship), 57% in
clinical practice 5% industry, 5% other, 7%
unknown pursuits.
Continued funding is expected for the program in 2003 since Merck Foundation funding
has been continuous over the past 13 years and
the NIH competitive renewal grant received an
outstanding score. Dr. Atchison hopes for even
more applicants and awards than in 2002.

